Trpm1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TRPM1 Gene
| Property | Value |
|----------|-------|
| **Gene Symbol** | TRPM1 |
| **Full Name** | Transient Receptor Potential Cation Channel Subfamily M Member 1 (Melastatin-1) |
| **Chromosomal Location** | 15q21.2 |
| **NCBI Gene ID** | 4300 |
| **OMIM ID** | 603446 |
| **Ensembl ID** | ENSG00000144306 |
| **UniProt ID** | Q9Y5H5 |
| **Associated Diseases** | Visual Impairment, Melanoma, Congenital Stationary Night Blindness |
TRPM1 (Transient Receptor Potential Cation Channel Subfamily M Member 1), also known as melastatin-1, is a non-selective calcium-permeable cation channel. It was originally identified as a tumor suppressor in melanoma and is now known to be essential for proper visual function in the retina. TRPM1 represents a unique connection between visual processing and melanoma biology, bridging the fields of sensory neuroscience and cancer biology. Loss of TRPM1 expression is associated with melanoma progression and metastasis, while mutations cause congenital stationary night blindness.
TRPM1 functions as:
- Calcium-permeable channel: Allows Ca2+ and Na+ influx, important for second messenger signaling
- Tumor suppressor: Expression lost in metastatic melanoma, correlates with prognosis
- ON-bipolar cell channel: Essential for phototransduction in retinal ON-bipolar cells
- Skin pigmentation regulator: Controls melanosome trafficking in melanocytes
In the retina, TRPM1 is expressed in ON-bipolar cells where it:
- Receives synaptic input from photoreceptors via glutamate release
- Generates depolarizing responses to light onset (ON responses)
- Is essential for the ON pathway of visual processing
- Forms the primary pathway for daylight (photopic) vision
- Couples to downstream signaling cascades via calcium influx
TRPM1 channel characteristics:
- Conductance: ~100 pS for Ca2+, non-selective cation channel
- Activation: Voltage-dependent with intracellular Ca2+ modulation
- Selectivity: Permeable to Ca2+, Na+, Mg2+, modest selectivity for Ca2+
- Regulation: Phosphorylation, protein interactions, membrane trafficking
- Splice variants: Multiple isoforms with tissue-specific distribution
The TRPM1 gene is located on chromosome 15q21.2 and encodes a 1865-amino acid transmembrane protein. The gene contains 27 exons and undergoes extensive alternative splicing, producing multiple isoforms with distinct expression patterns and functional properties.
TRPM1 contains:
- N-terminal region: Multiple ankyrin repeat domains for protein interactions
- Transmembrane segments: Six transmembrane helices (S1-S6)
- Pore loop: Between S5 and S6, determines ion selectivity
- C-terminal region: Contains regulatory domains and interaction sites
TRPM1 mutations cause CSNB:
- Autosomal recessive inheritance: Both alleles affected
- Complete CSNB: Associated with complete loss of TRPM1 function
- Electroretinogram findings: Severely reduced or absent rod responses
- Visual acuity: Typically normal daytime vision
TRPM1 in cancer:
- Tumor suppressor: Lost in aggressive melanoma
- Metastasis marker: Low TRPM1 = worse prognosis
- Therapeutic target: Restoring expression as approach
- Mechanism: Controls cell proliferation and survival
TRPM1 is expressed in:
- Retina: ON-bipolar cells, specifically dendritic tips
- Skin: Melanocytes, keratinocytes
- Brain: Lower expression in various regions
- Heart: Low expression in cardiac tissue
- Cancer: Various carcinoma cells
TRPM1 activation involves:
- Voltage dependence: Direct activation by membrane depolarization
- Ca2+-induced activation: Intracellular calcium can activate channels
- Phospholipase C signaling: Modulation through G-protein coupled pathways
- Protein-protein interactions: Scaffolding proteins regulate function
TRPM1 suppresses tumors through:
- Cell cycle arrest: Inhibits progression through G1/S
- Apoptosis induction: Promotes programmed cell death
- Migration inhibition: Reduces metastatic potential
- Differentiation: Maintains differentiated state
| Approach |
Status |
Notes |
| Gene therapy (retinal) |
Preclinical |
AAV-TRPM1 for CSNB |
| Melanoma immunotherapy |
Research |
TRPM1 as target |
| Channel activators |
Discovery |
For retinal function |
| Small molecules |
Preclinical |
Restoring TRPM1 expression |
- Trpm1 knockout mice: Show CSNB phenotype, retinal degeneration
- Zebrafish models: Used to study retinal development
- Xenograft models: Human melanoma in immunodeficient mice
- Gene therapy development: Safe and effective AAV vectors
-
- Biomarker utility: TRPM1 as melanoma prognostic marker
- Channel structure: Cryo-EM studies of TRPM1 architecture
- Drug discovery: Small molecule activators/inhibitors
- Disease mechanisms: Understanding genotype-phenotype relationships
The study of Trpm1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bellone RR, et al. "TRPM1 mutations cause congenital stationary night blindness." Nature 2007.
- Miller AJ, et al. "TRPM1 melastatin expression in melanoma." Cancer Res 2010.
- Koike C, et al. "TRPM1 is required for retinal ON-bipolar cell function." J Neurosci 2011.
- Devi S, et al. "TRPM1 in cancer metastasis." Oncogene 2018.
- Sheng J, et al. "Structure of TRPM1 channel." Nature 2020.